¼¼°èÀÇ ¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Pet Cancer Therapeutics Global Market Report 2025
»óǰÄÚµå : 1793385
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,328,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,147,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,966,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 10.6%¸¦ ³ªÅ¸³» 6¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº ¹Ý·Áµ¿¹°ÀÇ °í·ÉÈ­, ¾Ï Ä¡·áÀÇ Áøº¸, ¼öÀÇÁ¾¾çÇÐ ¼­ºñ½º Áõ°¡, ¹Ý·Áµ¿¹° º¸Çè°ú ÇコÄɾî Ç÷£, ¹Ý·Áµ¿¹° ÄÉ¾î ¼­ºñ½ºÀÇ ¼¼°èÀÇ È®´ë°¡ ¿äÀÎÀÔ´Ï´Ù. ¿¹Ãø±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¿µ¾çº¸Á¶½Äǰ°ú ÅëÇÕ¿ä¹ý Áõ°¡, Ç¥ÀûÁø´Ü°Ë»çÀÇ À̿밡´É¼º Áõ°¡, ¼öÀÇ»ç¿Í Àΰ£ÀÇ Á¾¾çÇÐÀÇ Á¦ÈÞ, ½Å±Ô È­Çпä¹ýÁ¦ÀÇ µµÀÔ, ÀǽÄÀÇ Çâ»ó°ú ÁÖÀα³À° µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 10.6%¶ó°í ÇÏ´Â ¿¹ÃøÀº ÀÌ ½ÃÀå¿¡ °üÇÑ ÀüȸÀÇ ¿¹ÃøÀ¸·ÎºÎÅÍ º¯°æÀº ¾ø½À´Ï´Ù. ÀÌ °¨¼ÒÀÇ ÁÖ¿ä ¿øÀÎÀº ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâÀÔ´Ï´Ù. ±¹Á¦ÀûÀ¸·Î Á¶´ÞµÇ´Â »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸é¿ª¿ä¹ý ÀԷ¿¡ ´ëÇÑ °ü¼¼ÀÇ ¿µÇâÀ¸·Î ¹Ý·Áµ¿¹°ÀÇ Ã·´Ü Á¾¾çÇÐ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º°ú °¡¿ë¼ºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼¿Í ¹«¿ª ±äÀå Áõ°¡¿Í Á¦ÇÑÀ¸·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ ±¤¹üÀ§ÇÏ°Ô ´Ã¾î³¯ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹Ý·Áµ¿¹° ÇコÄɾî ÁöÃâ Áõ°¡°¡ Àü¸ÁµÇ±â ¶§¹®¿¡ ¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ È®´ë°¡ Àü¸ÁµË´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ °Ç°­ °ü¸® ÁöÃâ¿¡´Â ¼öÀÇ»ç ¼­ºñ½º, Åõ¾à ¹× ±âŸ °Ç°­ °ü¸® °ü·Ã ºñ¿ë¿¡ ´ëÇÑ ÀÚ±ÝÀÌ Æ÷ÇԵ˴ϴÙ. ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ÅõÀÚÇÏ·Á°í ÇÏ´Â ÁÖÀÎÀÇ µ¿ÇâÀÇ ³ô¾ÆÁüÀÌ, ¹Ý·Áµ¿¹° ÇコÄɾÀÇ ÁöÃâ Áõ°¡¿¡ ¹Ý¿µµÇ¾î, ¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ºÏ¹Ì ¹Ý·Áµ¿¹° °Ç°­ º¸Çè Çùȸ(NAPHIA)ÀÇ 2023³â ¾÷°è ÇöȲ º¸°í¼­¿¡ µû¸£¸é 2022³â ¸»±îÁö ¹Ì±¹ ³» º¸Çè¿¡ °¡ÀÔÇÑ ¹Ý·Áµ¿¹° ¼ö°¡ 2021³â ´ëºñ 22% Áõ°¡ÇÏ¿© 480¸¸ ¸¶¸®¿¡ ´ÞÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ ¹Ý·Áµ¿¹° °Ç°­ °ü¸® ÁöÃâÀÇ ±ÞÁõÀÌ ¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ½ÃÀå ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. The choice of therapeutics depends on several factors such as the type and stage of cancer, as well as the pet's age and overall health.

The main types of pet cancer therapeutics are tailored to specific cancer types, including melanoma, mast cell cancer, lymphoma, and mammary and squamous cell cancer. Melanoma is a type of cancer that originates from pigment-producing cells called melanocytes. These therapeutics can be administered through various routes, including oral and injection methods, tailored for dogs, cats, and other animals. Different therapies employed in pet cancer treatment include chemotherapy, radiation therapy, immunotherapy, tomo therapy, and others. These therapies are utilized by veterinary hospitals, clinical pharmacies, retail pharmacies, online pharmacies, and other healthcare facilities focused on pet health.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The pet cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides pet cancer therapeutics market statistics, including pet cancer therapeutics industry global market size, regional shares, competitors with a pet cancer therapeutics market share, detailed pet cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pet cancer therapeutics industry. This pet cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pet cancer therapeutics market size has grown rapidly in recent years. It will grow from $0.39 billion in 2024 to $0.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to rise in pet ownership, advancements in veterinary medicine, increased awareness of pet health, humanization of pets, expansion of veterinary services.

The pet cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing aging pet population, advancements in cancer treatment, rising veterinary oncology services, pet insurance and healthcare plans, global expansion of pet care services. Major trends in the forecast period include rise in nutraceuticals and integrative therapies, increased availability of targeted diagnostic tests, collaboration between veterinary and human oncology, introduction of novel chemotherapeutic agents, growing awareness and pet owner education.

The forecast of 10.6% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff implications on biologics and immunotherapy inputs sourced internationally could limit accessibility and affordability of advanced pet oncology treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in pet healthcare expenditure is set to drive the expansion of the pet cancer therapeutics market. Pet healthcare expenditure encompasses the funds allocated for veterinary services, medications, and other healthcare-related costs for pets. The rising trend of pet owners' willingness to invest in their pets' well-being is reflected in the increased expenditure on pet healthcare, leading to a higher demand for pet cancer therapeutics. For example, the North American Pet Health Insurance Association's (NAPHIA) 2023 State of the Industry Report revealed a 22% increase in the total number of insured pets in the U.S. by the end of 2022, reaching 4.8 million, compared to 2021. This surge in pet healthcare expenditure is a driving force for the pet cancer therapeutics market.

The growth of the pet cancer therapeutics market is expected to be propelled by the increasing prevalence of pet cancer. Pet cancer involves abnormal and uncontrolled cell growth in domesticated animals, leading to tumor formation. The rising incidence of pet cancer is attributed to environmental toxins, pollutants, and genetic and lifestyle factors. Consequently, there is an escalating demand for advanced and effective cancer therapeutics for pets. According to the Veterinary Cancer Society's (VCS) 2022 predictions, approximately 1 in 4 dogs is diagnosed with cancer during their lifetime, with cancer being a primary cause of death among older pets. Additionally, the National Cancer Institute anticipates approximately 6 million new cancer cases in pets annually, with a projected increase in the coming years. The increasing prevalence of pet cancer is poised to drive the growth of the pet cancer therapeutics market.

Leading companies in the pet cancer therapeutics market are focusing on developing epigenetic technologies to enhance the efficacy of treatments and improve precision in targeting cancer cells, ultimately leading to better outcomes for pets diagnosed with cancer. Epigenetic technology involves techniques that modify gene expression without altering the underlying DNA sequence, thereby influencing cellular behavior and therapeutic results. For example, in April 2024, VolitionRx Limited, a US-based multinational epigenetics company, launched the Nu.Q Vet Cancer Test. This test operates on the Element i+ Analyzer and delivers rapid results-typically within approximately six minutes. It employs an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which can serve as indicators of cancer presence.

Strategic partnerships are a significant approach adopted by major companies in the pet cancer therapeutics market to achieve superior disease control. This collaborative strategy involves leveraging each other's strengths and resources to attain mutual benefits and success. One such collaboration occurred in June 2022, when Germany-based pharmaceutical company Boehringer Ingelheim partnered with U.S.-based biopharmaceutical company CarthroniX. The collaboration focuses on identifying new small molecules to target cancers in dogs, potentially offering superior disease control. CarthroniX will supply the small molecules for evaluation by Boehringer Ingelheim, emphasizing their commitment to advancing oncology research in animal health and exploring new therapeutic options for the treatment of canine cancer.

In June 2024, Lantheus, a US-based company specializing in the development and commercialization of innovative imaging products and radiopharmaceuticals for diagnostic purposes in healthcare, acquired Life Molecular Imaging GmbH for an undisclosed sum. This acquisition is intended to enhance Lantheus's portfolio of diagnostic imaging solutions, expand its capabilities in molecular imaging, and strengthen its position within the healthcare market. Life Molecular Imaging GmbH, based in Germany, is dedicated to advancing imaging technologies, particularly in the realm of molecular imaging.

Major companies operating in the pet cancer therapeutics market include AB Science, Boehringer Ingelheim GmbH, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., virology and bacteriology, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Dechra Pharmaceuticals plc, Norbrook Laboratories Ltd., AdvaVet Inc., Oasmia Pharmaceuticals AB, Zenoaq Co. Ltd., Morphogenesis Inc., Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc.

North America was the largest region in the pet cancer therapeutics market in 2024. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pet cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pet cancer therapeutics market consists of revenues earned by entities by surgery and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pet Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pet cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pet cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pet cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pet Cancer Therapeutics Market Characteristics

3. Pet Cancer Therapeutics Market Trends And Strategies

4. Pet Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pet Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

6. Pet Cancer Therapeutics Market Segmentation

7. Pet Cancer Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Pet Cancer Therapeutics Market

9. China Pet Cancer Therapeutics Market

10. India Pet Cancer Therapeutics Market

11. Japan Pet Cancer Therapeutics Market

12. Australia Pet Cancer Therapeutics Market

13. Indonesia Pet Cancer Therapeutics Market

14. South Korea Pet Cancer Therapeutics Market

15. Western Europe Pet Cancer Therapeutics Market

16. UK Pet Cancer Therapeutics Market

17. Germany Pet Cancer Therapeutics Market

18. France Pet Cancer Therapeutics Market

19. Italy Pet Cancer Therapeutics Market

20. Spain Pet Cancer Therapeutics Market

21. Eastern Europe Pet Cancer Therapeutics Market

22. Russia Pet Cancer Therapeutics Market

23. North America Pet Cancer Therapeutics Market

24. USA Pet Cancer Therapeutics Market

25. Canada Pet Cancer Therapeutics Market

26. South America Pet Cancer Therapeutics Market

27. Brazil Pet Cancer Therapeutics Market

28. Middle East Pet Cancer Therapeutics Market

29. Africa Pet Cancer Therapeutics Market

30. Pet Cancer Therapeutics Market Competitive Landscape And Company Profiles

31. Pet Cancer Therapeutics Market Other Major And Innovative Companies

32. Global Pet Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pet Cancer Therapeutics Market

34. Recent Developments In The Pet Cancer Therapeutics Market

35. Pet Cancer Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â